Daniel Starks Net Worth

11 Nov People

The estimated Net Worth of Daniel J Starks is at least $580 Million dollars as of 27 February 2018. Mr. Starks owns over 400 units of Abbott Laboratories stock worth over $579,994,865 and over the last 3 years he sold ABT stock worth over $0. In addition, he makes $300,977 as Independent Director at Abbott Laboratories.

Mr. Starks ABT stock SEC Form 4 insider trading

Daniel has made over 4 trades of the Abbott Laboratories stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 400 units of ABT stock worth $24,348 on 27 February 2018.

The largest trade he’s ever made was exercising 504,544 units of Abbott Laboratories stock on 2 August 2017 worth over $15,938,545. On average, Daniel trades about 71,817 units every 26 days since 2017. As of 27 February 2018 he still owns at least 7,013,239 units of Abbott Laboratories stock.

You can see the complete history of Mr. Starks stock trades at the bottom of the page.

Daniel Starks biography

Daniel J. Starks serves as Independent Director of the Company. Mr. Starks served as the Chairman, President and Chief Executive Officer of St. Jude Medical, Inc., from 2004 until his retirement in January 2016, after which he served as its Executive Chairman of the Board until January 2017, when Abbott completed the acquisition of St. Jude Medical, Inc. Mr. Starks also served as President and Chief Operating Officer of St. Jude Medical, Inc. from 2001 to 2004 and as its President and CEO, Cardiac Rhythm Management Business from 1997 to 2001. Having served as St. Jude Medical’s Executive Chairman and its Chairman, President and Chief Executive Officer, and having joined St. Jude Medical in 1996, Mr. Starks contributes not only comprehensive and critical knowledge of St. Jude Medical’s operations, but also extensive business and management experience operating a global public company in a highly regulated industry.

What is the salary of Daniel Starks?

As the Independent Director of Abbott Laboratories, the total compensation of Daniel Starks at Abbott Laboratories is $300,977. There are 14 executives at Abbott Laboratories getting paid more, with Miles White having the highest compensation of $24,254,200.

How old is Daniel Starks?

Daniel Starks is 64, he’s been the Independent Director of Abbott Laboratories since 2017. There are 5 older and 11 younger executives at Abbott Laboratories. The oldest executive at Abbott Laboratories is Samuel Scott, 74, who is the Independent Director.

What’s Daniel Starks’s mailing address?

Daniel’s mailing address filed with the SEC is 100 ABBOTT PARK ROAD, , ABBOTT PARK, IL, 60064.

Insider trading at Abbott Laboratories

Over the last 19 years, insiders at Abbott Laboratories have traded over $300,124,202 worth of Abbott Laboratories stock and bought 1,026,437 units worth $44,673,718 . The most active insider traders include Miles D White, Richard A Gonzalez, and Glenn F Tilton. On average, Abbott Laboratories executives and independent directors trade stock every 8 days with the average trade being worth of $3,036,946. The most recent stock trade was executed by Randel William Woodgrift on 23 October 2019, trading 21,000 units of ABT stock currently worth $1,691,340.

What does Abbott Laboratories do?

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

What does Abbott Laboratories’s logo look like?

Complete history of Mr. Starks stock trades at Abbott Laboratories

Abbott Laboratories executives and stock owners

Abbott Laboratories executives and other stock owners filed with the SEC include:

Miles White, Chairman of the Board, Chief Executive Officer
Robert Ford, President, Chief Operating Officer
Brian Yoor, Chief Financial Officer, Executive Vice President – Finance
Hubert Allen, Executive Vice President, General Counsel, Secretary
Daniel Salvadori, Senior Vice President – Established Pharmaceuticals, Latin America.
Robert Alpern, Independent Director
Sally Blount, Independent Director
Glenn Tilton, Independent Director
Samuel Scott, Independent Director
William Osborn, Lead Independent Director
Roxanne Austin, Independent Director
Edward Liddy, Independent Director
Nancy McKinstry, Independent Director
Phebe Novakovic, Independent Director
John Stratton, Independent Director
Daniel Starks, Independent Director
Michelle Kumbier, Independent Director
Darren McDew, Director
Jaime Contreras, Senior Vice President – Core Laboratory Diagnostics, Commercial Operations
Jared Watkin, Senior Vice President
Andrew H Lane, Senior Vice President
Robert E Funck, Senior Vice President
Sean Shrimpton, Senior Vice President
John M Capek, Executive Vice President
Deepak S. Nath, Senior Vice President
Joseph J Manning, Senior Vice President
Roger Bird, Senior Vice President
Brian J Blaser, Senior Vice President
Stephen R Fussell, Senior Vice President
Michael J Warmuth, Senior Vice President
Eric S Fain, Senior Vice President
Lisa D Earnhardt, Executive Vice President
Sharon J Bracken, Senior Vice President
Michael T Rousseau, Pres., Cardiovasc. & Neuromod.
Charles Brynelsen, Senior Vice President
Michael J Pederson, Senior Vice President
Alejandro D Wellisch, Senior Vice President
Sammy Karam, Senior Vice President
Randel William Woodgrift, Senior Vice President
Christopher J Scoggins, Senior Vice President
Richard W Ashley, Executive Vice President
Andrea F Wainer, Executive Vice President
John F Ginascol, Executive Vice President
Jean Yves Pavee, Senior Vice President
W James Farrell, Director
Thomas C Freyman, Senior Vice President
Georges H. De Vos, Senior Vice President
Katherine C. Doyle, Senior Vice President
J. Scott White, Senior Vice President
Charles D Foltz, Senior Vice President
Murthy V Simhambhatla, Senior Vice President
Thomas G Frinzi, Senior Vice President
John C Landgraf, Senior Vice President
Greg W Linder, Vice President
Heather L Mason, Senior Vice President
Paul K Magill, Senior Vice President
A. David Forrest, Senior Vice President
H Laurance Fuller, Director
Carlos Alban, Senior Vice President
James V Mazzo, Senior Vice President
Holger A Liepmann, Senior Vice President
William D Smithburg, Director
Laura J Schumacher, Senior Vice President
David Owen, Director
Edward L Michael, Senior Vice President
Richard A Gonzalez, Chief Operating Officer
Donald V Jr Patton, Senior Vice President
William M Daley, Director
Robert B Hance, Senior Vice President
Mary T Szela, Senior Vice President
Roy S Roberts, Director
Corlis D Murray, Senior Vice President
Thomas F Chen, Senior Vice President
Olivier Bohuon, Senior Vice President
James L Tyree, Senior Vice President
W Ann Reynolds, Director
Boone Jr Powell, Director
Mary K Moreland, Executive Vice President
Edward J Fiorentino, Senior Vice President
Gary E Mccullough, Senior Vice President
Jeffrey M Leiden, President & COO
Jack M Greenberg, Director
Joseph M Nemmers, Senior Vice President
John R Walter, Director
Jeffrey R Binder, Senior Vice President
William G Dempsey, Senior Vice President
A Barry Rand, Director
Thomas M Wascoe, Senior Vice President
Christopher B Begley, Senior Vice President
Lance B Wyatt, Senior Vice President
Guillermo A Herrera, Senior Vice President
Lasa Jose M De, Senior Vice President

Daniel Starks Net Worth